CAR-T Cell Therapy

Executive Summary Chimeric Antigen Receptor (CAR) T-cell therapy represents a paradigm shift in the treatment of refractory or relapsed hematologic malignancies. This form of adoptive cell transfer (ACT) involves the genetic engineering of autologous T-cells to express synthetic receptors that target specific tumor-associated antigens, independent of Major Histocompatibility Complex (MHC) presentation. Current FDA-approved therapies primarily…